Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
PRTA Stock Chart & Stats
$10.65
<$0.01(0.07%)
At close: 4:00 PM EST
$10.65
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$4.32 - $18.88
Previous CloseN/A
Volume58.73K
Average Volume (3M)732.47K
Market Cap
$573.29M
Enterprise Value-$34.92M
Total Cash (Recent Filing)$371.44M
Total Debt (Recent Filing)$9.78M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Oct 30, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,829,930
10 Day Avg. Volume686,318
30 Day Avg. Volume732,465
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-3.38
Enterprise Value/Gross Profit-3.70
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$16.50Price Target Upside54.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Strategic PartnershipsProthena's arrangement with partners offers asymmetric upside that is not reflected in the current valuation.
Therapeutic DevelopmentRoche has confirmed plans to initiate a Phase 3 trial of prasinezumab in early Parkinson’s disease, building on a Phase 2b signal that suggested slowed motor progression.
UndervaluationRecent updates reinforce the thesis that PRTA is currently undervalued, with the market assigning zero credit to two late-stage partnered assets targeting multi-billion dollar markets.
Bears Say
Prothena News
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $4.32 and its highest was $18.88 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $573.29M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Oct 30, 2025 which is today.
How were Prothena’s earnings last quarter?
Currently, no data Available
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.69.
How many shares outstanding does Prothena have?
Prothena has 53,829,930 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.50 (54.93% Upside)
$16.50 (54.93% Upside)
Hedge Fund Trend
Increased
By 34.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.39%
12-Months-Change
Fundamentals
Return on Equity
-66.85%
Trailing 12-Months
Asset Growth
-38.18%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc is a biotechnology company focused on discovering and developing novel therapeutics for the treatment of neurodegenerative diseases and cancer. The company leverages its expertise in protein misfolding and aggregation to create innovative therapies, primarily in the areas of amyloid-related diseases such as Alzheimer's and Parkinson's disease, along with other protein misfolding disorders. Prothena's pipeline includes several clinical-stage programs, highlighting its commitment to addressing unmet medical needs with its proprietary technology platform.
PRTA Stock 12 Month Forecast
Average Price Target
$16.50
▲(54.93% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Xoma
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Ownership Overview
24.47% Insiders
20.01% Mutual Funds
0.31% Other Institutional Investors
49.13% Public Companies and
Individual Investors